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Kaposi’s sarcoma-associated herpesvirus (KSHV) is associated with Kaposi’s sarcoma (KS), primary effu-
sion lymphoma (PEL), and multicentric Castleman’s disease. Most KS tumor cells are latently infected with
KSHV and are of endothelial origin. While PEL-derived cell lines maintain KSHV indefinitely, all KS
tumor-derived cells to date have lost viral genomes upon ex vivo cultivation. To study KSHV latency and
tumorigenesis in endothelial cells, we generated telomerase-immortalized human umbilical vein endothelial
(TIVE) cells. TIVE cells express all KSHV latent genes 48 h postinfection, and productive lytic replication
could be induced by RTA/Orf50. Similar to prior models, infected cultures gradually lost viral episomes.
However, we also obtained, for the first time, two endothelial cell lines in which KSHV episomes were
maintained indefinitely in the absence of selection. Long-term KSHV maintenance correlated with loss of
reactivation in response to RTA/Orf50 and complete oncogenic transformation. Long-term-infected TIVE cells
(LTC) grew in soft agar and proliferated under reduced-serum conditions. LTC, but not parental TIVE cells,
formed tumors in nude mice. These tumors expressed high levels of the latency-associated nuclear antigen
(LANA) and expressed lymphatic endothelial specific antigens as found in KS (LYVE-1). Furthermore, host
genes, like those encoding interleukin 6, vascular endothelial growth factor, and basic fibroblast growth factor,
known to be highly expressed in KS lesions were also induced in LTC-derived tumors. KSHV-infected LTCs
represent the first xenograft model for KS and should be of use to study KS pathogenesis and for the validation
of anti-KS drug candidates.
Kaposi’s sarcoma-associated herpesvirus (KSHV), also called
human herpesvirus 8 (HHV-8), is believed to be the causative
agent for Kaposi’s sarcoma (KS) (for a review, see references
1 and 27). Within KS tumor lesions, the majority of cells
express endothelial markers and are latently infected with
KSHV, as defined by the presence of the circular viral genome
and limited viral-gene expression. Studying KSHV’s role in KS
is complicated by the fact that cells explanted from KS lesions
lose the KSHV genome after several cell divisions in culture (2,
43). In addition to KS, KSHV is associated with two lympho-
proliferative diseases: primary effusion lymphomas (PEL) and
multicentric Castleman’s disease (MCD) (11, 59). In contrast
to KS lesions, PEL-derived cell lines that are latently infected
with KSHV are readily established in culture. These cells
maintain viral episomes indefinitely and remain dependent on
KSHV for survival (31, 33). Therefore, many aspects of KSHV
biology have been studied in PEL-derived cell lines rather than
in endothelial cells (56; for a review, see reference 1).
Several endothelial-cell-derived tissue culture models have
been described. Common to these models, which are based on
dermal microvascular endothelial cells (DMVEC), are their
susceptibility to cell-free infection with PEL-derived KSHV
and their capability to support lytic replication, both sponta-
neously and upon induction with the phorbol ester tetradeca-
noyl phorbol acetate (TPA) (13, 23, 41, 48). With respect to the
maintenance of latency and the induction of phenotypic
changes following KSHV infection, significant differences have
been reported: (i) telomerase-immortalized microvascular en-
dothelial (TIME) cells are susceptible to KSHV infection but
cannot support long-term episomal maintenance (41), and
(ii) Ciufo et al. reported on persistent infections in primary
DMVEC consisting of a mixture of latently and lytically in-
fected cells. Because both the formation of spindle cells and
the number of latently infected latency-associated nuclear an-
tigen (LANA)-expressing cells decreased in the presence of
phosphoformic acid (PFA), an inhibitor of lytic DNA replica-
tion, these data suggested that lytic replication and reinfection
contributed to long-term viral persistence (13, 38). Supporting
this model, Grundhoff and Ganem demonstrated that most
epithelial and endothelial cell types fail to efficiently support
stable latency after in vitro infection (32). DMVEC immortal-
ized by the papillomavirus proteins E6/E7 (targeting the major
tumor suppressor proteins p53 and pRB) and infected by
KSHV exhibit spindle cell formation and outgrowth of cells
with altered attachment requirements and changes in host cell
gene expression, such as up-regulation of c-Kit. Such changes
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were observed by maintaining these cells under long-term cul-
ture (48). Finally, primary bone marrow-derived endothelial
cells were transformed after KSHV infection in vitro. This
model was the first to highlight the paracrine effects of KSHV
infection. In this system, too, KSHV is gradually lost, and less
than 5% of cells in a mixed culture remain KSHV infected
(23).
Here, we report on a novel umbilical-cord-derived vein en-
dothelial-cell model that is highly susceptible to KSHV and
supported high-level lytic replication early after infection.
Most cells lost the viral episomes over time; however, we also
obtained telomerase-immortalized human umbilical-vein endo-
thelial (TIVE) cell cultures that stably support KSHV latency
in the absence of selection and that underwent marked phe-
notypical changes. Long-term-infected TIVE cells (LTC), but
not uninfected TIVE cells, formed colonies in soft agar and
efficiently induced tumor formation in nude mice. Analysis of
these tumors revealed histological features and expression of
the same surface markers that define KS tumors. Hence, LTC
provide a novel and unique model to study KSHV pathogen-
esis in vivo in a human endothelial-cell-specific manner.
MATERIALS AND METHODS
Primary cells, cell lines, and KSHV stocks. Umbilical cord-derived endothelial
cells were isolated by collagenase treatment and grown in Fisher M199 medium
supplemented with 15% fetal calf serum (FCS) and 5 ml of filtered endothelial-
cell growth factors (ECGF) as previously described (30). The primary effusion
lymphoma line BCBL-1, as well as the procedures for inducing and harvesting
KSHV virions, have been described previously (54). Infections of TIVE cells
were done in the presence of Polybrene (4 g/ml), as previously described (41).
Vectors and retroviral transduction. pBabe/puro/hTert was kindly provided by
Robert Weinberg (Massachusetts Institute of Technology). As a control, we used
MFG-GFP vector. Ten micrograms of each vector was cotransfected with 15 g
of pVSV-G for pseudotyping into Phoenix-Ampho packaging cells (kindly pro-
vided by Garry Nolan, Stanford University). The supernatants were harvested
48 h posttransfection and filtered, and NIH 3T3 cells were used to determine
viral titers. For transduction of human vein endothelial cells (HUVEC), cells at
50% confluence were incubated with human telomerase reverse transcriptase
(hTert) or green fluorescent protein (GFP) virus in the presence of Polybrene (8
g/ml) for 8 h. Virus-containing medium was replaced with new virus and
incubated for a second period of 12 h, after which the medium was replaced with
fresh medium. Three days postinfection, the cells were divided into two flasks,
and one was puromycin treated. To monitor life spans, MFG-GFP-transduced
HUVEC and nontransduced cells from the same primary cell preparation were
cultivated in parallel.
Analysis of viral gene products and cellular surface markers. Immunofluores-
cence assays and Western blot analysis for LANA and K8.1 were performed as
previously described (12). Antibodies were kindly provided by Don Ganem (Uni-
versity of California—San Francisco) and Bala Chandran (University of Kansas).
Immunohistochemical analyses were performed using commercially available an-
tibodies against CD31, CD34, CD45, CD68, CD105, Flt, keratin, SMSA, UEA,
S100A10, and factor VIII (also called von Willebrand factor [vWF]). For develop-
ment, a secondary antibody conjugated to alkaline phosphatase was used. Tumors
were removed and fixed in 10% neutral buffered formalin (Fisher Diagnostic) for 2
days, embedded in paraffin blocks, and processed by routine methods, and 5-m
sections were obtained. Dewaxed sections were microwaved in 1 mM EDTA (pH 8)
for PCNA and lymphatic endothelial specific antigens as found in KS (LYVE-1) and
Retrievagen A (BD Pharmingen, San Diego, CA) for rabbit polyclonal antibody to
LANA of HHV-8 for 15 min, cooled, and treated with 3% H2O2 (Sigma) in 10%
methanol to inhibit endogenous peroxidase activity, blocked with blocking solution
with 10% horse serum (Vector Laboratories, Burlingame, CA), and incubated over-
night with the appropriate primary antibody at 1:200 dilution. PCNA (FL-261) rabbit
polyclonal immunoglobulin G was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA); anti-LYVE-1 rabbit immunoaffinity-purified immunoglobulin G was
purchased from Upstate (Lake Placid, NY); rabbit polyclonal antibody to LANA of
HHV-8 was from D. Ganem; and phosphate-buffered saline (PBS) was used as the
negative control. After being washed, sections were stained for 1 h with a goat
anti-rabbit biotinylated horseradish peroxidase H-conjugated secondary antibody,
followed by Avidin DH (VECTASTAIN ABC kit; Vector Laboratories, Burlin-
game, CA). The sections were washed in PBS and incubated for 5 min with Vector
NovaRed substrate for peroxidase (Vector Laboratories, Burlingame, CA). The
slides were counterstained with hematoxylin (Sigma).
Colony formation in soft agar. First, a base layer containing 0.5% agarose medium
and 5% FCS was poured into six-well plates. Then, 10,000 cells were mixed with
0.4% agarose in Earl’s minimal essential medium (EMEM) containing 5% FCS to
form a single-cell suspension. After being seeded, the plates were incubated for 2
weeks. To establish clones, single colonies were picked and transferred into 96-well
plates for expansion.
Mouse tumorigenesis assays. Cells were counted and washed once in ice-cold
PBS (Cellgro Mediatech, Inc., Herndon, VA), and the indicated cell doses were
diluted in 50 l PBS plus 50 l growth factor-depleted Matrigel (BD Biosciences,
Bedford, MA). Cells were injected subcutaneously into the right flanks of nude
BALB/c mice (Taconic, Inc., Germantown, NJ). The mice were observed every
day for the presence of palpable tumors. The tumors were excised from the site
of injection and were either fixed in formalin (Fisher Diagnostics, Middletown,
VA) or resuspended in TRI reagent (Sigma-Aldrich Corp., St. Louis, MO) and
processed for reverse transcription (RT)-PCR.
Flow cytometry analysis. To determine the DNA content, cells were fixed and
DNA was stained with propidium iodide prior to flow cytometry analysis using a
FACScan analyzer (Becton Dickinson, Mountain View, CA). Data were ana-
lyzed using ModFit Lt V3 software (Verity Software House).
Gardella gel analysis. To prove episomal genome maintenance, 50,000 to 100,000
long-term-infected TIVE cells and BCBL-1 cells (TPA treated) as controls were
loaded into lysis buffer, electrophoresed on vertical 0.8% agarose gels, transferred to
membranes, and analyzed by Southern blotting as previously described (55).
KSHV array analysis. Poly(A) mRNA of TIVE cells, KSHV-infected TIVE
cells at 3 months and 10 months, KSHV-infected long-term culture SLK cells,
and BCBL-1 cells were prepared and subjected to real-time RT-PCR using the
previously published KSHV array and procedures (50). Solid tumor pieces were
resuspended in 750 l TRI Reagent (Sigma-Aldrich Corp., St. Louis, MO) and
disrupted using an Ultra-Turrax T8 (IKA Labortechnik, Germany). RNA was
isolated according to the supplier’s protocol, precipitated, and resuspended in 50
l diethyl pyrocarbonate-treated water at 56°C for 10 min. The RNA was reverse
transcribed as described previously (3) in a 20-l reaction mixture with 100 U of
Moloney murine leukemia virus reverse transcriptase (Life Technologies, Carls-
bad, CA), 2 mM deoxynucleoside triphosphates, 2.5 mM MgCl2, 1 U RNAsin (all
from Applied Biosystems, Foster City, CA), and 0.5 g of random hexanucle-
otide primers (Amersham Pharmacia Biotech, Piscataway, NJ). The RT reaction
mixture was sequentially incubated at 42°C for 45 min, 52°C for 30 min, and 70°C
for 10 min. The reaction was stopped by heating the mixture at 95°C for 5 min.
Finally, 0.5 l of RNase H (Life Technologies, Carlsbad, CA) was added to the
RT reaction mixture, which was then incubated at 37°C for 30 min and heat
inactivated at 70°C for 10 min, and cDNA pools were stored at 80°C.
Quantitative real-time PCR. Quantitative real-time PCR primers were de-
signed using Primer Express 1.5 (Applied Biosystems, Foster City, CA) and used
as previously described (18, 21) on an ABI PRIZM 5700 Sequence Detector
(Applied Biosystems, Foster City, CA) using universal cycling conditions (2 min
at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at
60°C). The cycle threshold (CT) values were determined by automated analysis.
The threshold was set to five times the standard deviation of the nontemplate
control. Dissociation curves were recorded after each run, and the amplified
products were routinely analyzed by 2% agarose gel electrophoresis.
Raw CT values were normalized to GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) to yield dCT. The primers in this array had a mean amplification
efficiency of 1.9  0.1, which was used to calculate fold induction as 1.9ddCT. To
identify potential deletion in the KSHV genome in long-term-cultured TIVE
cells, DNA was extracted and PCR was carried out by using the primers in the
KSHV array mentioned above.
Gene expression profiling and data analysis. Total RNA was extracted from
TIVE and KSHV-infected TIVE cells at 3 and 10 months postinfection by using
Rnazol (Teltest Inc., Friendswood, TX) as recommended by the manufacturer.
Gene expression profiling was performed by Case Western Reserve University
and the Ireland Cancer Center Gene Expression core facility using Affymetrix
technology. All experiments were performed using oligonucleotide-based HG-
U95Av2 chips that contained 12,626 probe sets corresponding to human genes
and expressed sequence tags. All procedures, starting with the selection of
mRNA, reverse transcription, and the generation of biotin-11-CTP- and biotin-
16-UTP (Enzo Diagnostics)-labeled cRNA by T7 in vitro transcription, were
performed as recommended by Affymetrix and as previously published (3).
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Statistical analysis of data and pairwise comparisons were done using Affymetrix
MAS 5.0 software. A detailed description of the analysis was given by An et al.
(3), and the original data can be viewed at NCBI gene expression omnibus
(GEO).
Statistical analysis. Calculations were performed using Excel (Microsoft Inc.,
Redwood, WA) and SPSS v. 11.0 (SPSS Science, Chicago, IL). Hierarchical
clustering was performed as previously described (3, 50). All samples were
normalized to GAPDH, centered by the median of the gene, normalized to 1,
and ordered by hierarchical clustering using ArrayMiner software (Optimal
Design Inc., Brussels, Belgium).
Nucleotide sequence accession number. The original data can be viewed at
NCBI GEO (accession number GSE1880 [GSM33151, 33152, 33153]).
FIG. 1. Immunohistochemical analysis of hTert-immortalized HUVEC in comparison to primary HUVEC; staining for CD31, CD34, CD45,
CD68, CD105, Flt, keratin, SMSA, UEA, S100A10, and factor VIII (vWF) expression. The left-hand panels show primary HUVEC at passage 2.
The right-hand panels show TIVE cells. TIVE cells strongly express five endothelial-cell-specific markers (CD31, CD105, Flt, UEA, and factor
VIII), but not CD45, keratin, or SMSA, which shows slight background staining compared to the primary antibody control (Negative mouse). Note
the slightly more elongated morphology of TIVE in contrast to the characteristic cobblestone morphology of HUVEC.
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RESULTS
Establishment of a telomerase-immortalized HUVEC line.
Ectopic expression of hTert has been successfully utilized to
establish immortalized cell lines of several different lineages (7,
62). Primary umbilical cord-derived HUVEC at passage 2 were
transduced with VSV G protein-pseudotyped retrovirus con-
taining either pBabe/hTert or pBabe/GFP packaged in Phoe-
nix cells (kindly provided by G. Nolan, Stanford University).
Transduced cells under selection and primary HUVEC were
passaged and fed biweekly. After passage 10, both primary
HUVEC and pBabe/GFP-transduced cells stopped proliferat-
ing. Cells transduced with pBabe/hTert continued to divide. To
ensure that endothelial lineage characteristics were maintained
after hTert immortalization, a detailed analysis of surface
markers was performed. As shown in Fig. 1 and summarized in
Table 1, 100% of the cells expressed the endothelial-cell-spe-
cific markers CD31, Flt, UEA, CD105, and factor VIII/vWF.
CD34, a marker for hematopoietic progenitors and some en-
dothelial cells, which is also expressed in KS tumors, was de-
tectable at low levels in HUVEC at passage 2 and was nearly
undetectable in TIVE cells. Expression of CD45, a lymphoid
marker, was not detectable, and SMSA, a fibroblastoid marker,
showed some background levels. Except for CD34, the ob-
served expression patterns at passage 12 were identical to
those of primary umbilical-cord-derived HUVEC at passage 2
(Fig. 1), supporting the notion that hTERT-dependent immor-
talization does not affect cell lineage commitment. Similar to
the previously published TIME cells, which are telomerase-
immortalized endothelial cells of dermal microvascular origin
(41), we called this cell line TIVE for telomerase-immortalized
vein endothelial cells. TIVE cells can be propagated once a
week at a ratio of 1 to 3 and remain dependent on ECGF. To
date, TIVE cells have been cultured continuously for more
than 35 passages.
TIVE cells are susceptible to KSHV infection and support
lytic replication early after infection. TIVE cells were inocu-
lated with BCBL-1-derived cell-free virus at a multiplicity of
infection of 10 (based on genome equivalents) and analyzed by
immunofluorescence assays (IFA) for the expression of LANA, a
reliable marker for infection (16, 19, 29, 39). Nearly 100% of the
cells expressed LANA at 48 h postinfection (Fig. 2A). To confirm
the specificity of the IFA signal, TIVE cells were inoculated with
serially diluted cell-free KSHV, and the number of LANA-posi-
tive cells decreased accordingly (Fig. 2B). Hence, TIVE cells are
susceptible to cell-free KSHV infection.
To determine whether TIVE cells support lytic replication,
KSHV-infected cells at 48 h postinfection were either TPA
treated or infected with a recombinant adenovirus expressing
FIG. 2. TIVE cells are susceptible to KSHV and support lytic rep-
lication early after infection. (A) LANA IFA on TIVE cells 48 h
postinfection with BCBL-1-derived KSHV. (B) Threefold serial dilu-
tions of BCBL-1-derived cell-free virion preparations. The error bars
indicate standard deviations. (C) KSHV-infected TIVE cells can be
induced to lytic replication. TIVE cells were infected with KSHV or
mock infected; 48 h later, the cells were infected with Ad-Orf50, and
cell lysates were analyzed by Western blot analysis 72 h later. KSHV-
infected SLK cells were used as positive controls. All KSHV-infected
cells expressed LANA (lanes 1, 3, and 4). KSHV-infected and -induced
TIVE cells expressed significantly more K8.1 than SLK cells. Tubulin
was used as a loading control.















Factor VIII (vWF)  
a Endothelium-specific markers are in boldface type. P2, passage 2.  and 
indicate relative expression levels.
4836 AN ET AL. J. VIROL.
the major lytic transactivator RTA (Ad-Orf50) for 72 h (6, 56).
Five days post-KSHV infection, the cells were analyzed for
expression of K8.1, a late lytic marker. Characteristic K8.1
staining was observed in about 10% of the cells (data not
shown). Western blot analysis showed K8.1 expression that was
significantly stronger in infected TIVE cells than in KSHV-
infected and -induced SLK cells, which are susceptible to
KSHV infection but have been reported to poorly support lytic
replication (Fig. 2C) (6). Serial transmission using superna-
tants from KSHV-infected, TPA-induced TIVE cells to infect
naı̈ve TIVE cells was performed three consecutive times and
produced LANA-positive cells (see Fig. S1 in the supplemental
material). These data show that TIVE cells are susceptible to
KSHV, and furthermore, that infected cells can be induced to
lytic replication early after infection.
Outgrowth of KSHV-infected TIVE cells that support long-
term latency. To determine whether infected TIVE cells could
support latency while continuously dividing, we repeat pas-
saged TIVE cells at subconfluency. KSHV-infected TIVE cells
(90% LANA positive) were split 1 to 3 once a week and
analyzed for LANA and K8.1 expression. LANA expression
decreased to less than 10% at week 4, while K8.1 was unde-
tectable after 4 weeks (Fig. 3A). The percentages of K8.1-
expressing cells observed by IFA at 1 week postinfection varied
considerably between experiments and may have represented
spontaneously reactivating cells. Using PCR, we observed a
steady loss of viral genomes between weeks 4 and 10 postin-
fection (Fig. 3B). Hence, TIVE cells do not efficiently support
latency and long-term episomal maintenance. Similar out-
comes were observed in many experiments, and these data are
consistent with published observations of KSHV-infected
TIME cells, suggesting that long-term maintenance of KSHV
in cultured endothelial cells is inefficient (32, 41).
We also observed cases in which TIVE cells remained
KSHV positive. As shown in Fig. 4A, after 5 weeks, 8 weeks,
and even 10 months, these cells remained 100% LANA posi-
tive. LANA expression was confirmed in two cultures by West-
ern blot analysis (Fig. 4B). IFA for both K8.1 and ORF59 were
negative; thus, lytic infection was undetectable (data not
shown). To further demonstrate latency in contrast to persis-
tence, which requires reinfection, we cultured KSHV-infected
TIVE cells for eight passages in the presence of PFA (200
M), which blocks lytic replication (38). In contrast to prior
reports (41), the frequency of LANA-positive cells was not
altered in the presence of PFA (Fig. 4C). This demonstrates
that in LTC, latent but not lytic replication is sufficient for
long-term maintenance of KSHV.
Long-term-infected TIVE cells undergo phenotypic changes
reminiscent of transformation. During long-term culture, KSHV-
infected TIVE cells underwent notable phenotypic changes. Un-
infected TIVE cells grow relatively slowly and are dependent on
endothelial-cell growth factors. Initially, KSHV-infected TIVE
cells shared these characteristics. However, after 6 to 8 weeks,
KSHV-infected cells in two parallel experiments started dividing
significantly faster, grew to confluent monolayers, and displayed
criss-cross morphology, indicating the loss of contact inhibition.
We therefore tested their growth phenotype in soft agar, a widely
used assay to assess transformation (17). TIVE or KSHV-infected
TIVE cells were seeded into semisolid media and incubated for
14 days. While TIVE cells did not form colonies, KSHV-infected
cells at both 3 and 10 months postinfection formed colonies in
soft agar (Fig. 5A). To confirm the viability of these cells, we
picked 10 colonies and established subclones (LTC 1 to 10). LTC
lost their dependence on ECGF, could be split at higher ratios (1
to 10), and had a significantly shorter cell cycle than uninfected
TIVE cells, as documented by the much higher proportion of cells
in S phase (38% for LTC compared to 10% for TIVE cells) (Fig.
5B). To verify the presence of episomal KSHV DNA in these
cells, we performed Gardella gel analysis on five LTC clones. As
shown in Fig. 5C, KSHV episomal DNA was readily detectable
(8, 18, 60) and migrated at the same position as BCBL-1-derived
episomes. This analysis demonstrates the presence of KSHV epi-
somes—however, it does not rule out the presence of integrated
KSHV DNA. In sum, LTC represent the first endothelial-cell-
derived tumor cell lines in which 100% of the cells are latently
infected with KSHV.
LTC express latency-associated genes but do not efficiently
reactivate from latency. Next, we examined viral-gene expres-
sion during latency and after induction of lytic replication.
Genomewide gene expression analysis was performed using a
real-time quantitative RT-PCR assay as previously published
(18, 21). This assay simultaneously probes for the expression of
more than 80 viral genes; three cellular genes are used for
normalization. Two LTC clones were analyzed and compared
to long-term-infected SLK cells and BCBL-1 cells. Figure 6A
FIG. 3. KSHV-infected TIVE cells lose viral genomes over time.
TIVE cells were infected with BCBL-1-derived cell-free KSHV as
described in Materials and Methods. At the indicated time points, the
cells were analyzed for the expression of LANA and K8.1 and for the
presence of viral DNA. (A) IFA for LANA and K8.1. The percentage
of LANA-positive cells declined from greater than 95% at week 1 to
less than 10% at week 4. A significant percentage of the cells expressed
K8.1 at 1 week postinfection; this expression was undetectable at week
4. (B) Detection of viral DNA by PCR. Genomic DNA extracted at the
indicated time points was amplified using 25 cycles. The DNA copy
number decreased between weeks (W) 4 and 10.
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shows the viral expression profile from these assays in the form
of a heat diagram. LTC and SLK cells express the major
latency-associated genes LANA, v-cyclin, and v-Flip, which are
expressed from a single genomic locus (16, 58, 63). BCBL-1
cells express the same set of genes, but also some lytic genes,
due to a small percentile of spontaneously reactivating cells
(12, 56). By comparison, KSHV gene expression in LTC is
tightly latent, reminiscent of viral-gene expression in the ma-
jority of spindle cells in KS lesions (Fig. 6A, compare lanes 2,
3, and 4) (8, 18, 60).
To analyze and compare gene expression during lytic repli-
cation, cultures were either treated with TPA or infected with
a recombinant adenovirus expressing the major lytic transacti-
vator RTA (Ad-Orf50) (6) and were analyzed by real-time
RT-PCR as described above. Raw data were averaged and
normalized to GAPDH (to yield dCT values). Next, the dCT for
each gene under induced conditions was plotted against the
dCT values under uninduced conditions. Hence, dCT values
that did not change in the presence or absence of induction fell
on a diagonal line, while induced genes shifted down.
As expected for BCBL-1 cells, TPA and Ad-Orf50 induced
a marked induction of a large number of KSHV genes, indic-
ative of efficient lytic replication (Fig. 6B). In LTC, only Ad-
Orf50 infection led to minor expression changes affecting a
much smaller number of genes, including orf57, a direct target
of Orf50 (Fig. 6C). In contrast, Ad-Orf50 infection of long-
term-infected SLK cells led to a genomewide induction of gene
expression (Fig. 6D). These data demonstrate that LTC do not
efficiently reactivate from latency.
To confirm these results independently of PCR, we treated
LTC with either TPA or Ad-Orf50 and analyzed cell lysates by
Western blotting for the expression of K8.1, a late lytic marker.
A blot representative of eight total experiments is shown in
Fig. 6E. BCBL-1 cells treated for 48 h with TPA or analyzed 5
days post-Ad-Orf50 infection efficiently expressed K8.1 (Fig.
6E, lanes 2 and 3). In contrast, no K8.1 expression was detect-
able in KSHV-infected TIVE cells after TPA treatment or
Ad-Orf50 infection for either 2 or 5 days (Fig. 6E, lanes 4 to 6)
under conditions where Ad-GFP infected more than 90% of
cells (Fig. 6F). Identical assay conditions efficiently induced
lytic replication in TIVE cells and SLK cells 2 days postinfec-
tion (Fig. 2C). We note that the assay sensitivity permitted
detection of K8.1 in uninduced BCBL-1 cells, with less than
0.5% of cells expressing K8.1 (12).
To rule out any major deletions of the KSHV genome in
LTC clones, we extracted genomic DNA and performed
genomewide DNA PCR analysis using the primer set described
above. We were not able to detect any differences between
BCBL-1- and LTC-derived genomes (data not shown). These
data demonstrate that latency in long-term-infected TIVE cells
is tightly regulated. At this point, we do not know where the
block in reactivation lies. The fact that even in the presence of
FIG. 4. KSHV-infected TIVE cells support long-term latency. (A) LANA IFA on KSHV-infected TIVE cells 5 and 8 weeks and 10 months
postinfection. IFA at 10 months was analyzed by confocal microscopy and double stained with anti-LANA antibodies (green) and propidium iodide
(red). (B) LANA detection by Western blot analysis in TIVE cells (lane 1) or KSHV-infected TIVE cells 3 months (lane 2) and 10 months (lane
3) postinfection. (C) Western blot analysis of KSHV-infected TIVE cells that were grown in the presence of 0.5 mM PFA for eight consecutive
passages; as a loading control, membranes were stripped and incubated with an -tubulin-specific antibody (P indicates passage numbers).
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RTA, only a small number of genes, including orf57, were
up-regulated suggests epigenetic modifications of the KSHV
genome—however, other possibilities cannot be ruled out at
this point and will be discussed below.
LTC express many cellular genes that are highly expressed
in KS lesions. Next, we analyzed cellular transcriptomes of
LTC and TIVE cells. Comparative gene expression profiling
was performed on TIVE cells and LTCs at 3 and 10 months
postinfection using Affymetrix HG-u95Av2 arrays. RNA ex-
traction, cRNA synthesis, hybridization, washing, and data
analysis were performed as previously described (3). All pri-
mary data are available at NCBI GEO. Compared to TIVE
cells, LTC at 3 or 10 months postinfection showed 1,639 and
1,694 expression changes (2-fold up or down), of which 869
changes were common to both time points. For the purpose of
validating LTC as a model for KS, we focused on two groups of
genes. KS lesions are characterized by extensive neoangiogen-
esis and high levels of cytokine expression (20). In comparison
to uninfected TIVE cells, KSHV-positive LTC expressed vas-
cular endothelial growth factor (VEGF) (10- and 13.9-fold),
basic fibroblast growth factor (8- and 9.2-fold), and its recep-
tors FGFR1 (2.1- and 2.3-fold) and FGFR4 (6.5- and 4-fold).
Interleukin 6 (IL-6), also commonly detected in KS lesions,
was induced 2.5-fold in LTC (Table 2).
Since LTC express LANA, we hypothesized that LANA-
responsive cellular genes would be induced. LANA regulates
viral- and cellular-gene expression in KSHV-associated malig-
nancies. LANA interacts with the tumor suppressors p53 and
RB and modulates the Wnt pathway by stabilizing -catenin.
As a result, LANA promotes S-phase entry and protects cells
from apoptosis (24–26, 52). Further supporting these molecu-
lar interactions, we recently reported that of a total of 181 gene
expression changes observed in LANA-inducible B-cell lines,
41 (23%) were related to RB/E2F signaling (3). Performing a
similar analysis on the LTC data set revealed a total of 130
genes (15%) that have been classified as RB/E2F related (45,
49, 53); 19 genes overlapped between LTC and the 41 genes
shown to be regulated by LANA. These genes are involved in
cell cycle control (CDC25A, cyclin E1, RBP4, and ID1) and
DNA synthesis (TTK, TYMS, and DHFR) (Table 2, and NCBI
GEO accession number GSE1880). Hence, the overall gene
expression profile of LTC at 3 and 10 months postinfection
shows a pattern that resembles some important aspects of KS
lesions.
Long-term-infected TIVE cells efficiently form tumors in
nude mice. Based on the resemblance between KS tumors and
LTC (endothelial origin, episomal KSHV maintenance, latent
KSHV gene expression, and cellular gene expression profile),
we tested LTC in comparison to uninfected TIVE cells for the
ability to form tumors in vivo. Nude mice where injected sub-
cutaneously with 5  105 TIVE cells in Matrigel as previously
described (61). Five mice received LTC at 3 months postinfec-
tion, while a second group of five mice received LTC at 10
months postinfection; three mice were injected with uninfected
TIVE cells. The animals were visually inspected daily, and the
first tumors were palpable around day 7. At day 21 postinocu-
lation, 10/10 mice from both LTC groups had developed tu-
mors approximately 10 to 15 mm in diameter (Fig. 7B and C),
while TIVE cell-injected animals did not develop any tumors
even after 48 weeks (Fig. 7A). These results are statistically
FIG. 5. KSHV-infected TIVE cells display phenotypic changes indicative of transformation. (A) Colony formation assay of TIVE cells or LTC
at 3 months and 10 months postinfection; 10,000 cells each were seeded as single-cell suspensions into semisolid media containing EMEM and 5%
FCS, and colony growth was scored 2 weeks postinfection. (B) LTC divide faster than TIVE cells. Comparative cell cycle analysis after propidium
iodide staining of TIVE cells and LTC. A significantly higher proportion of LTC (39%) than uninfected TIVE cells (10%) were in S phase.
(C) Gardella gel analysis of LTC. Five LTC clones established from colonies shown in panel A were analyzed for the presence of episomal KSHV
genomes. TPA-induced BCBL-1 cells were loaded as controls to indicate circular and linear genome migration, as previously described (24).
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significant (P  0.007, using nonparametric statistics) and show
that LTC, but not TIVE cells, are tumorigenic in mice (Fig.
7D). Mice bearing tumors were sacrificed at day 21, and the
tumors were analyzed by histology and immunohistochemistry.
Hematoxylin and eosin staining of LTC-induced tumors re-
vealed a mixture of elongated spindle cells and undifferenti-
ated morphology with prominent mitotic figures. In contrast to
PEL-derived tumor models (61), there was no well-differenti-
ated layer of cells surrounding the blood vessels. Rather, the
tumor cells retained the ability to compose the blood vessel
FIG. 6. Comparative genomewide gene expression profiling of LTC and SLK and BCBL-1 cells during latency and after induction of lytic replication;
genomewide real-time RT-PCR analysis of LTC-derived tumors. (A) Cluster analysis of multiple experiments, comparing the induction profiles of orf50
and TPA for SLK (lane 1), BCBL-1 (lane 2), and two different LTC (lanes 3 and 4). Each cell line is represented by three columns: uninduced, TPA
treated, and Ad-Orf50 infected. The arrows denote the most induced mRNAs, and the bars indicate mRNAs that are not induced. The grayscale indicates
the relative level of transcription, normalized to GAPDH. Black indicates the most abundant mRNAs on a log2 scale. (B, C, and D) Comparative gene
expression analysis of BCBL-1 and SLK cells and LTC in response to TPA or Ad-Orf50. The vertical axis indicates dCT values, normalized to GAPDH,
for actin (open triangles), orf50 (open circles), and orf57 (closed squares). A decrease in deltaCT represents increased levels on a log2 scale. Panel C plots
dCT values on the vertical axis for mock-treated (gray squares), TPA-treated (open circles), and Ad-Orf50-treated (black triangles) cells relative to
mock-treated cells on the horizontal axis for BCBL-1 cells (B), LTC (C), or SLK cells (D). (F) LTC do not efficiently reactivate from latency. Western
blot analysis for K8.1 on BCBL-1 cells and long-term-infected LTC clones. LTC clones or BCBL-1 cells as controls were infected with recombinant
Ad-Orf50 for 5 days or treated with TPA for 48 h. The cell lysates were tested for K8.1 expression. K8.1 was highly induced in either TPA- or
Ad-Orf50-infected cells (lanes 2 and 3). LTC did not express any detectable level of K8.1 (shown is one representative result from a total of eight similar
experiments). (E) LTC are susceptible to adenovirus infection. TIVE cells express GFP 48 h postinfection with Ad-GFP.
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TABLE 2. Expression changes of cytokine genes and Rb/E2F pathway-related genes in LTC TIVE cells compared to TIVE cells
No. Access no.a LTC change(n-fold) Symbol Gene name
M83667 2.5 IL-6 Interleukin 6
AF024710 13.9 VEGF Vascular endothelial growth factor
J04513 9.2 bFGF Basic fibroblast growth factor
1 U22398 64 CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2)
2 U69263 27.9 MATN2 Matrilin 2
3 X70340 19.7 TGF- Transforming growth factor alpha
4 M97287 16 SATB1 Special AT-rich sequence binding protein 1
5 U30930 14.9 UGT8 UDP glycosyltransferase 8
6 U60805 13.9 OSMR Oncostatin M receptor
7 AF053305 13 BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog
8 M34677 13 F8A1 Coagulation factor VIII-associated (intronic transcript) 1
9 X15187 12.1 TRA1 Tumor rejection antigen (gp96) 1
10 J00140 12.1 DHFR Dihydrofolate reductase, alternate splice 6
11 U12535 11.3 EPS8 Epidermal growth factor receptor pathway substrate 8
12 U81607 9.2 AKAP12 A kinase (PRKA) anchor protein (gravin) 12
13 X51345 8.6 JUNB junB proto-oncogene
14 M64347 7 FGFR3 Fibroblast growth factor receptor 3
15 U61262 7 NEO1 Neogenin homolog 1 (chicken)
16 L07540 6.1 RFC5 Replication factor C (activator 1) 5; 36.5 kDa
17 X98172 5.7 CASP8 Caspase 8; apoptosis-related cysteine protease
18 U59831 5.7 FOXD1 Forkhead box D1
19 L37882 5.7 FZD2 Frizzled homolog 2 (Drosophila)
20 U65410 5.7 MAD2L1 MAD2 mitotic arrest deficient-like 1
21 X84373 5.7 NRIP1 Nuclear receptor interacting protein 1
22 U01038 5.7 PLK1 Polo-like kinase 1 (Drosophila)
23 X60673 5.3 AK3L1 Adenylate kinase 3-like 1
24 AF058696 5.3 NBS1 Nijmegen breakage syndrome 1 (nibrin)
25 X89750 5.3 TGIF TGF--induced factor (TALE family homeobox)
26 S78825 4.9 ID1 Inhibitor of DNA binding 1
27 AF017790 4.9 KNTC2 Kinetochore associated 2
28 M15205 4.6 TK1 Thymidine kinase 1; soluble
29 X76029 4.3 NMU Neuromedin U
30 U89606 4.3 PDXK Pyridoxal (pyridoxine; vitamin B6) kinase
31 M86699 4.3 TTK TTK protein kinase
32 U18934 4.3 TYRO3 TYRO3 protein tyrosine kinase
33 X51956 4 ENO2 Enolase 2 (gamma, neuronal)
34 AB014458 4 USP1 Ubiquitin-specific protease 1
35 U18932 3.7 NDST1 N-Deacetylase/N-sulfotransferase 1
36 X06745 3.7 POLA Polymerase (DNA directed) alpha
37 M73812 3.5 CCNE1 Cyclin E1
38 X65550 3.5 MKI67 Antigen identified by monoclonal antibody Ki-67
39 U03911 3.5 MSH2 mutS homolog 2; colon cancer; nonpolyposis type 1
40 AF029669 3.5 RAD51C RAD51 homolog C (Saccharomyces cerevisiae)
41 J04088 3.5 TOP2A Topoisomerase (DNA) II alpha; 170 kDa
42 X02308 3.5 TYMS Thymidylate synthetase
43 AJ223728 3.2 CDC45L CDC45 cell division cycle 45 like (S. cerevisiae)
44 L19779 3.2 HIST2H2AA Histone 2 H2aa
45 M88108 3.2 KHDRBS1 KH domain containing; RNA
46 AF030234 3.2 SFRS2IP Splicing factor: arginine/serine rich 2
47 U18271 3.2 TMPO Thymopoietin
48 AF049105 3 CEP2 Centrosomal protein 2
49 X00088 3 HIST1H2BJ Histone 1 H2bj
50 Z24459 3 MTCP1 Mature T-cell proliferation 1
51 U21090 3 POLD2 Polymerase (DNA directed) delta 2
52 U66618 3 SMARCD2 SWI/SNF related; matrix/actin/chromatin; member 2
53 Y08837 3 XRCC2 X-ray repair in Chinese hamster cells 2
54 X05360 2.8 CDC2 Cell division cycle 2; G1 to S and G2 to M
55 M81933 2.8 CDC25A Cell division cycle 25A
56 M63256 2.8 CDR2 Cerebellar degeneration-related protein 2; 62 kDa
57 U65093 2.8 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich c-2
58 X54942 2.8 CKS2 CDC28 protein kinase regulatory subunit 2
59 U61145 2.8 EZH2 Enhancer of zeste homolog 2 (Drosophila)
60 U75362 2.8 USP13 Ubiquitin-specific protease 13 (isopeptidase T-3)
61 Z22535 2.6 BMPR1A Bone morphogenetic protein receptor; type IA
62 L41887 2.6 SFRS7 Splicing factor; arginine/serine rich 7; 35 kDa
63 U61234 2.6 TBCC Tubulin-specific chaperone c
64 AB009356 2.5 MAP3K7 Mitogen-activated protein kinase kinase kinase 7
Continued on following page
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TABLE 2—Continued
No. Access no.a LTC change(n-fold) Symbol Gene name
65 D87953 2.5 NDRG1 N-myc downstream regulated gene 1
66 X74262 2.5 RBBP4 Retinoblastoma binding protein 4
67 U46751 2.5 SQSTM1 Sequestosome 1
68 L36720 2.3 BYSL Bystin like
69 X98743 2.3 DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18
70 AF012108 2.3 NCOA3 Nuclear receptor coactivator 3
71 AB003103 2.3 PSMD12 Proteasome 26S subunit; non-ATPase; 12
72 L20859 2.3 SLC20A1 Solute carrier family 20; member 1
73 U76366 2.3 TCOF1 Treacher-Collins-Franceschetti syndrome 1
74 D89052 2.1 ATP6V0B ATPase; H transporting; V0 subunit c
75 M14745 2.1 BCL2 B-cell CLL/lymphoma 2
76 U20980 2.1 CHAF1B Chromatin assembly factor 1; subunit B (p60)
77 Z80780 2.1 HIST1H2BE Histone 1 H2be
78 M60725 2.1 RPS6KB1 Ribosomal protein S6 kinase; 70 kDa; polypeptide 1
79 AF075587 2 MYCBP2 MYC binding protein 2
80 M60858 2 NCL Nucleolin
81 U61232 2 TBCE Tubulin-specific chaperone e
82 U70987 2 DOK1 Docking protein 1; 62 kDa
83 X91648 2 PURA Purine-rich element binding protein A
84 U63824 2 TEAD4 TEA domain family member 4
85 M61176 2.1 BDNF Brain-derived neurotrophic factor
86 L24559 2.1 POLA2 Polymerase (DNA directed); alpha 2 (70-kDa subunit)
87 AF034956 2.1 RAD51L3 RAD51-like 3 (S. cerevisiae)
88 L20298 2.3 CBFB Core-binding factor; beta subunit
89 D38524 2.3 NT5C2 5	-nucleotidase, cytosolic II
90 U43142 2.3 VEGFC Vascular endothelial growth factor C
91 X58521 2.5 NUP62 Nucleoporin; 62 kDa
92 Z36714 2.6 CCNF Cyclin F
93 AC004770 2.6 FADS3 Fatty acid desaturase 3
94 D64110 2.8 BTG3 BTG family; member 3
95 AF002668 2.8 DEGS1 Degenerative spermatocyte homolog 1; lipid
96 U76638 3 BARD1 BRCA1-associated RING domain 1
97 L78833 3 VAT1 Vesicle amine transport protein 1 homolog (Torpedo californica)
98 X17094 3.2 FURIN Furin (paired basic amino acid-cleaving enzyme)
99 AF051321 3.2 KHDRBS3 KH domain; RNA binding; signal transduction associated 3
100 U43899 3.2 STAM Signal transducing adaptor molecule (SH3 and ITAM) 1
101 AF047472 3.5 BUB3 BUB3 budding uninhibited by benzimidazoles 3 homolog
102 D86550 3.5 DYRK1A Dual-specificity tyrosine-(Y)-phosphorylation kinase 1A
103 J04111 3.5 JUN v-jun sarcoma virus 17 oncogene homolog (avian)
104 U63825 4 DIPA Hepatitis delta antigen-interacting protein A
105 U63717 4.3 OSTF1 Osteoclast-stimulating factor 1
106 J03764 4.3 SERPINE1 Serine (or cysteine) proteinase inhibitor; clade E; member 1
107 M22490 4.6 BMP4 Bone morphogenetic protein 4
108 AF072250 4.6 MBD4 methyl-CpG binding domain protein 4
109 J03802 4.6 PTHLH Parathyroid hormone-like hormone
110 X72889 4.6 SMARCA2 SWI/SNF related; matrix/actin/chromatin/member 2
111 S66431 4.9 JARID1A Jumonji; AT-rich interactive domain 1A (RBBP2-like)
112 X87843 4.9 MNAT1 Ménage à trois 1 (CAK assembly factor)
113 X15507 4.9 Hox5.4 Homeotic protein Hox 5.4
114 D87119 5.7 TRIB2 Tribbles homolog 2 (Drosophila)
115 D87292 6.5 TST Thiosulfate sulfurtransferase (rhodanese)
116 M85289 8.6 HSPG2 Heparan sulfate proteoglycan 2 (perlecan)
117 M31166 12.1 PTX3 Pentraxin-related gene,; rapidly induced by IL-1
118 U16954 14.9 AF1Q ALL1-fused gene from chromosome 1q
119 X03473 17.1 H1F0 H1 histone family; member 0
120 U67784 18.4 CMKOR1 Chemokine orphan receptor 1
121 M64497 18.4 NR2F2 Nuclear receptor subfamily 2; group F; member 2
122 J02854 22.6 MYL9 Myosin; light polypeptide 9; regulatory
123 U68723 29.9 CHES1 Checkpoint suppressor 1
124 Z37976 68.6 LTBP2 Latent transforming growth factor beta binding protein 2
125 X52947 78.8 GJA1 Gap junction protein alpha 1; 43 kDa (connexin 43)
126 M22489 104 BMP2 Bone morphogenetic protein 2
127 X93510 119.4 PDLIM4 PDZ and LIM domain 4
128 X82209 128 MN1 Meningioma (disrupted in balanced translocation) 1
129 L27560 207.9 IGFBP5 Insulin-like growth factor binding protein 5
130 U03877 256 EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1
a Boldface genes were also found to be changed in B lymphocytes expressing LANA in an inducible fashion (3); the full data set can be found at NCBI GEO
(accession no. GSE1880).
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lining, and erythrocytes extravasated into the tumor (Fig. 8A).
Importantly, every cell in these tumors expressed the charac-
teristic nuclear speckled pattern for LANA (Fig. 8B and C).
KSHV infection of primary HUVEC cells induced differenti-
FIG. 7. LTC are highly tumorigenic in NUDE mice. Uninfected
TIVE cells or LTC (105 cells in growth factor-depleted Matrigel)
established at 3 or 10 months postinfection were injected subcutane-
ously into nude mice. (A, B, and C) Mice injected with LTC at 3 (5/5)
and 10 (5/5) months developed tumors, while none of the control mice
injected with TIVE cells (0/3) did. (D) Graph indicating the size and
distribution of resulting tumors. Pairwise comparisons using sum-rank
statistics demonstrate statistical significance. Boxes represent inter-
quartile ranges; lines within boxes represent the medians; T bars indi-
cate highest and lowest observed values.
FIG. 8. LTC-derived tumor cells express LANA and LYVE-1 and
show a more permissive viral expression pattern than LTC grown in
vitro. LTC-derived tumors were dissected and analyzed for protein and
viral-mRNA expression. (A) Hematoxylin and eosin staining of L1
tumor displaying a mixture of elongated-spindle-cell and undifferen-
tiated morphologies with prominent mitotic figures. The inset shows
tumor cells closely surrounding a blood vessel. The arrowheads indi-
cate erythrocytes extravasated into the tumor. (B and C) Immunohis-
tochemical detection of LANA, LYVE-1, and PCNA. Shown is one
representative panel out of five tumor samples. Panel C shows an
enlarged tissue section from panel B to emphasize typical LANA
speckled staining. (D) Genomewide real-time RT-PCR analysis of
LTC-derived tumors. The graph shows mean expression levels from
pooled mRNA samples taken from a total of five LTC-derived tumors
(two at 3 months and 3 at 10 months postinfection). The data are
plotted as dCT in comparison to GAPDH and LTC. A much broader
gene expression pattern in tumors than in LTC grown in vitro is shown.
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ation into the lymphatic endothelium, for which LYVE-1 is a
marker (10, 34, 64). LYVE-1 is also expressed on KS spindle
cells. To test the hypothesis that LTC maintained this pheno-
type, we stained tumor sections with antibodies for LYVE-1.
We also stained the tumor sections with PCNA, which is a
marker for proliferating cells. The majority of cells stained
positive for both antigens, suggesting that LTC-induced tu-
mors display features of KS lesions (Fig. 8B).
LTC-derived tumors express both latent and lytic genes.
Within KS lesions, the majority of cells are latently infected.
However, a small number of cells in each tumor also express
lytic markers, and the proportions of lytic-gene expression vary
between KS biopsies (8, 18, 60). This maybe important for
pathogenesis, since many potential KSHV-encoded pathogen-
esis modifiers (i.e., vGPCR, K1, K3, and K5) are not expressed
during latency in PEL (14, 36, 40, 42). Therefore, a model has
been proposed in which a relatively small number of cells
reactivate and actively contribute to tumor homeostasis through
paracrine effects (4, 32). At this point, it is unresolved whether
these cells actively replicate virus or simply show a more ex-
tensive pattern of early gene expression. To determine viral-
gene expression in LTC-derived tumors, we analyzed five dis-
sected LTC-derived tumors by genomewide quantitative
real-time RT-PCR. Figure 8D shows the mean expression level
(n 
 5) of KSHV mRNAs relative to GAPDH mRNA levels
and in comparison to LTC that were cultivated in vitro. In
tumors, about 25% of all KSHV mRNAs were present at 10%
of GAPDH mRNA levels. The mRNAs for orf55, orf17, orf4,
gM, helicase, and K7 were present at or above the level of
LANA mRNA (Fig. 8D). These observations were in stark
contrast to the tightly regulated latent gene regulation ob-
served in LTC when cultured in vitro (Fig. 6). Hence, in vivo
growth of KSHV-infected LTC is associated with a more per-
missive viral transcription pattern. A similar phenotype was
reported when latently infected PEL cells were transplanted
into mice (61). In summary, these data demonstrate that in
vitro-infected LTC, when introduced into mice, generate a
tumor that recapitulates hallmark features of KS lesions. To
date, LTC represents the first and only xenograft model for KS
tumors based on in vitro-infected human endothelial cells.
DISCUSSION
TIVE cells provide a novel cell type in which to study KSHV
biology. As demonstrated by cell surface marker expression,
TIVE cells preserved a typical endothelial phenotype after
transduction with hTert (Fig. 1 and Table 1). Consistent with
previous reports demonstrating that hTert expression alone
does not lead to alterations in p53 and/or Rb pathways, TIVE
cells did not grow in soft agar or form tumors in mice (Fig. 5
and 7) (47). Like primary endothelial cells (HUVEC) or im-
mortalized endothelial cells, TIVE cell cultures are susceptible
to cell-free KSHV infection and support lytic replication early
after infection (Fig. 2). Phenotypically, early TIVE cell passages
more closely resemble primary HUVEC than either TIME cells
(41) or E6/E7-immortalized HUVEC, in which many pathways
targeted by latency-associated genes are deregulated prior to in-
fection with KSHV (24, 26, 48, 52). TIVE cells complement these
existing models and are useful to study aspects of latent and lytic
replication early after infection. Like other endothelial-cell cul-
ture systems, TIVE cells infected with KSHV lose the viral ge-
nome over time (32) (Fig. 3). However, the outgrowth of two
KSHV long-term-infected TIVE cell lines provide for the first
time the opportunity to study latency in endothelial cells that
support long-term episomal maintenance. The growth pheno-
types of these two cell lines in soft agar allowed us to establish 10
LTC clones, which remained 100% KSHV infected (Fig. 4 and 5).
Hence, in the TIVE model, maintenance of the viral episome is a
clonal, cell-autonomous phenotype. The frequency of this event is
low, which is consistent with cellular transformation and can be
rationalized analogously to the emergence of androgen-indepen-
dent clones in early-stage prostate cancer cell lines. Preliminary
data from transfecting LANA-specific small interfering RNA
constructs into LTC suggested that, as recently demonstrated for
PEL cells (15, 31), latent KSHV gene expression may also directly
contribute to the survival of LTC (R. Renne, unpublished data).
Therefore, further development of TIVE-like cell lines may ulti-
mately be useful to determine KSHV genes whose expression
contributes to tumorigenesis in the context of the intact viral
genome, comparable to the outgrowth of lymphoblastoid cell
lines in response to Epstein-Barr virus infection of human B cells
(44).
In contrast to previously described DMVEC-based models,
LTC do not reactivate spontaneously from latency. Indeed,
even the expression of Ad-Orf50 did not induce efficient lytic
replication (Fig. 6). However, in vitro-cultured LTC expressed
the major latency-associated genes of KSHV that are highly
expressed in KS lesions. Once introduced into mice, the result-
ing tumors showed a more permissive gene expression profile
reminiscent of a minority of cells within KS lesions (8, 60) (Fig.
8). Our preliminary gene expression profiling data revealed a
large number of cellular genes whose expression was associ-
ated with KS tumors (e.g., VEGF, basic fibroblast growth fac-
tor, and IL-6) (Table 2). Therefore, a more detailed expression
analysis of LTC in comparison to LTC tumors will provide
insights into the cellular-gene expression profile of KS cells. So
far, cellular-gene expression studies with KSHV-infected cells
have used either PEL-derived cell lines, de novo-infected en-
dothelial-cell lines, or primary cells that represent a mixture of
latently and lytically infected cells (3, 13, 22, 37).
Many lines of evidence point to LANA, v-cyclin, and v-Flip
as essential players in KS pathogenesis. LANA, like simian
virus 40 large T antigen, is a replication/transcription factor
that modulates the major tumor suppressors p53 and RB (5,
24, 35, 52). Recently, LANA has also been shown to directly
affect the Wnt/-catenin signaling pathway in lymphomas,
which is altered in many human malignancies (25, 26). In this
context, it is important that TIVE cells have not been immor-
talized by viral oncogenes, such as E6/E7, that prevent studies
of the above-mentioned signaling pathways. Hence, TIVE cells
early after infection with KSHV and long-term-infected LTC
provide a cell culture model in which to study latency and its
potential role in KSHV-dependent tumorigenesis.
Until now, all reported KSHV tumor models have utilized
PEL-derived cell lines or cells transfected with individual
KSHV ORFs encoding potential oncogenes (4, 28, 46). This
is largely due to the lack of endothelial cells that stably
maintained KSHV after in vitro infection. However, PEL lym-
phomagenesis, which is closely tied to B-cell maturation in
germinal centers, differs from the development of KS disease
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(22, 37). Hence, the generation of stably infected LTC and the
fact that LTC (10/10) but not TIVE cells (0/3) efficiently
formed tumors in nude mice represent the first xenograft
model for KS. Moreover, the analysis of LTC-derived tumors
revealed many features observed in KS lesions, including the
expression of LYVE and angiogenic cytokines, such as VEGF
and IL-6 (Fig. 7 and 8). LTC-derived tumors recapitulate many
virological and cellular characteristics of KS tumors; therefore,
newly developed and existing drugs could be tested for efficacy
to inhibit tumor growth in this model.
Very recently, several groups have reported on the identifica-
tion of KSHV-encoded microRNAs (miRNAs) within the laten-
cy-associated region of KSHV (9, 51, 57). miRNAs posttranscrip-
tionally modulate cellular- and/or viral-gene expression and might
represent a new class of viral genes that contribute to pathogen-
esis. KSHV-encoded miRNAs are transcribed in LTC and LTC-
derived tumors at a level comparable to those of other mRNAs in
the LANA latency cluster (D. P. Dittmer and R. Renne, unpub-
lished data) and will provide a unique opportunity to functionally
analyze miRNA expression during latent and lytic replication in
vivo (57).
Finally, this model will aid studies of the contributions of
latent and lytic genes to KSHV-dependent pathogenesis and
tumorigenesis in vivo. Within this context, we found viral-gene
expression to be much more permissive in LTC-derived tumors
(Fig. 8D) than in LTC grown in vitro (Fig. 6C). These obser-
vations are in agreement with gene expression in KS tumors, as
well as with previous observations on PEL-derived tumor mod-
els (61), and suggest that the tumor microenvironment is cru-
cial in modeling host-viral interactions as present in KS dis-
ease.
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